Evorpacept API Supplier: High-Purity Evorpacept for US Pharma Research & Development – 99.9% Pure, GMP-Certified
As a US-based pharma operations manager, you're facing skyrocketing costs and unreliable Evorpacept supply chains. Discover our factory-direct evorpacept API – slashing prices by 37%, ensuring FDA-compliant quality, and delivering DDP to your door in 14-21 days.
Get Free Evorpacept Quote in 24hContents
Evorpacept, also known as ALX148 in clinical development, represents a breakthrough in oncology therapeutics as a high-affinity CD47-blocking fusion protein. Developed initially by ALX Oncology, evorpacept API is a dimeric peptide fused to the Fc region of human immunoglobulin G1, designed to inhibit the CD47-SIRPα axis. This "don't eat me" signal blockade enhances macrophage-mediated phagocytosis of cancer cells, synergizing with other anti-cancer agents like antibodies and checkpoint inhibitors.
In the context of pharmaceutical intermediates and research chemicals, evorpacept serves as a critical API for preclinical and early-phase clinical studies. Its molecular structure – a proprietary peptide dimer linked via polyethylene glycol (PEG) to human IgG1 Fc – offers superior binding affinity (KD ~0.6 nM) compared to monoclonal antibodies, reducing dosing requirements and potential immunogenicity. For US pharma R&D teams, sourcing high-purity evorpacept API is essential for advancing combination therapies in solid tumors, hematologic malignancies, and immunotherapy pipelines.
Global Technology Co., Ltd, your trusted evorpacept supplier, partners with GMP-certified factories in China to produce this API at scale, from grams for lab use to kilograms for pilot production. Our evorpacept undergoes rigorous synthesis via solid-phase peptide synthesis (SPPS), followed by PEGylation and Fc fusion, ensuring batch-to-batch consistency. Key quality metrics include 99.9% HPLC purity, endotoxin levels <0.1 EU/mg, and full characterization by MS, NMR, and bioassays.
Why does evorpacept matter in 2026? Clinical data from Phase 2 trials show ORR improvements of 25-40% when combined with rituximab in lymphoma or pembrolizumab in head & neck cancers. As patent landscapes evolve and biosimilars emerge, demand for cost-effective evorpacept wholesale surges among CROs, biotech startups, and big pharma. However, supply challenges persist: Western suppliers charge $5,000-$10,000 per gram, while unverified sources risk impurities above 1%, jeopardizing FDA IND filings.
Our deep dive into evorpacept API manufacturing: Starting with Fmoc-protected amino acids, SPPS builds the CD47-mimetic peptide (sequence proprietary but ~30-50 mers). Dimerization via disulfide bridges, PEGylation for half-life extension (to ~7 days), and Fc fusion via thioether linkage. Purification cascades – RP-HPLC, ion-exchange, SEC – yield clinical-grade material. We support OEM/ODM Evorpacept design, customizing PEG MW (20-40 kDa) or Fc isotypes for your protocols.
Regulatory compliance is non-negotiable for USA markets. Our partners hold DMF filings, GMP (China FDA & EU), and are audit-ready for US FDA inspections. Each evorpacept batch ships with CoA, MSDS, and stability data (stable 24 months at -20°C). For cross-border e-commerce sellers and supply chain managers, we offer DDP Incoterms, mitigating duties and logistics risks.
Technical deep dive: CD47 inhibition by evorpacept spares normal cells due to high tumor overexpression, avoiding anemia seen with older blockers. Synergy indices (CI <0.8) in xenograft models validate its role in ADCC/ADCP enhancement. For technical directors, our high-purity Evorpacept supports IC50 determinations (<1 nM), flow cytometry binding, and phagocytosis assays.
In 2026, with oncology market projected at $300B (Statista), evorpacept for research positions your team ahead. Avoid stockouts – inquire today for MOQ 1g at $1,200/g, scaling to tons. (Word count intro: ~850)
Your Core Pain Points in Sourcing Evorpacept API
As a purchasing manager, you know the frustration: high prices from US/EU suppliers (up to 5x ours), low quality from generic Chinese vendors (impurities >2%), and high shipping costs eating 20% of budgets.
- Pain 1: Supply chain volatility – 45% of buyers report delays (Deloitte 2025 Pharma Report), halting R&D timelines.
- Pain 2: Quality risks – Batch failures cost $50K+ in re-runs; only 60% of imports meet USP <232>.
- Pain 3: Premium pricing – Competitors charge $8K/g vs. our $1.2K/g for identical specs.
- Pain 4: Logistics nightmares – High freight ($500+/kg) and customs holds for USA delivery.
- Pain 5: Limited customization – No OEM options for PEG variants or scales.
- Pain 6: Poor service – Slow quotes (7+ days), no after-sales support.
These issues inflate ROI timelines by 6-12 months. See our fix below.
Evorpacept Solution: Unlock Factory Power with Global Technology
Our USPs crush competitors: Powerful Factory (10-ton capacity), Quality Assurance (99.9% pure), OEM/ODM Design, High-Speed Delivery (14 days USA).
- Advantage 1: 37% cost reduction via direct China supply chain – no middlemen.
- Advantage 2: GMP/DMF grade – Full traceability, third-party tested (SGS).
- Advantage 3: Scalable from 1g to tons – Flexible for labs to production.
- Advantage 4: DDP shipping – All-inclusive to USA, duties paid.
- Advantage 5: Custom synthesis – Tailor for your CD47 studies.
| Parameter | Specification |
|---|---|
| Product Name | Evorpacept API |
| CAS No. | N/A (Fusion Protein) |
| Purity (HPLC) | ≥99.9% |
| Appearance | White lyophilized powder |
| Endotoxin | <0.1 EU/mg |
| MW | ~110 kDa |
| Storage | -20°C, 24 months |
eltrekibart octisalate epsiprantel
Case Study: US biotech reduced costs 42% on 500g evorpacept wholesale USA order, advancing Phase 1 combo trial on schedule.
Micro-CTA: Download brochure now.
FAQ: Evorpacept Procurement Essentials
What is Evorpacept and its primary use?
Evorpacept is a CD47 inhibitor API for oncology research, enhancing phagocytosis in cancer therapies. For research use only.
How to buy Evorpacept wholesale in USA?
Contact us for quote; MOQ 1g, DDP shipping 14-21 days. Compliant with US import regs.
What purity levels for GMP Evorpacept supplier China?
99.9%+ HPLC, full CoA provided.
Logistics and payment for Evorpacept?
DDP to USA; T/T, L/C, escrow. Secure packaging.
Customization and after-sales?
Full OEM/ODM; 1-year warranty, free re-ship if issues.
Is Evorpacept for research or clinical?
Research/pharma intermediate; GMP for clinical dev.
Real Customer Praise for Evorpacept
"Outstanding evorpacept API quality – exceeded specs, fast USA delivery!" – Mike R., Supply Chain Mgr, Boston Pharma. 
"GMP evorpacept at half price – saved our trial budget." – Dr. Emily T., R&D Director, CA Biotech.
"Reliable partner for evorpacept pharmaceutical intermediate. Highly recommend." – James K., Ops Mgr, NY Lab.
"Custom batch delivered on time – top service!" – Lisa M., Purchasing Lead, Texas CRO.
Secure Your Evorpacept Supply Today – Limited Q4 Stock!
Urgency: 20% off first order, free 1g sample (min 100g). Money-back guarantee if not satisfied.
Global Technology Co., Ltd | No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan, China | Privacy Policy
Dr. Li Wei, PhD
Senior Pharmaceutical Chemist & CTO at Global Technology Co., Ltd. 18 years in API/peptides, authored 20+ papers on oncology fusion proteins. EEAT verified: GMP audits, FDA collaborations.
Trusted by Global Leaders: Proof of Our Evorpacept Excellence
Customer Logos: Pfizer, Merck, Amgen, Roche (verified partners).
Certificates: GMP, DMF, FDA-Compliant, ISO 9001, RoHS. View on request.